SEC Form 4 · accession 0001209191-15-045635
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curtis Ruegg
Officer — EVP, Technical Operations
Period of report
May 19, 2015
Accepted (ET)
May 21, 2015 · 6:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 19, 2015 | F | 1,310 | $25.94 | D | 18,027 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the number of shares withheld by and surrendered to the Issuer on May 19, 2015, to satisfy tax withholding obligations that arose in connection with the vesting of the Restricted Stock Award ("RSA") for 10,500 shares. The RSA vests in three equal annual installments from May 19, 2014, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.